Walleye Capital LLC Has $12.89 Million Stake in Dianthus Therapeutics, Inc. $DNTH

Walleye Capital LLC decreased its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 25.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 153,585 shares of the company’s stock after selling 52,230 shares during the quarter. Walleye Capital LLC’s holdings in Dianthus Therapeutics were worth $12,889,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. First Horizon Corp bought a new stake in shares of Dianthus Therapeutics during the first quarter worth $32,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Dianthus Therapeutics in the fourth quarter valued at about $40,000. Raymond James Financial Inc. acquired a new position in Dianthus Therapeutics during the 2nd quarter worth about $27,000. Russell Investments Group Ltd. acquired a new position in Dianthus Therapeutics during the 3rd quarter worth about $64,000. Finally, Royal Bank of Canada grew its holdings in Dianthus Therapeutics by 36.9% during the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after acquiring an additional 542 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Down 2.8%

Shares of DNTH opened at $102.76 on Thursday. The stock’s fifty day simple moving average is $89.98 and its 200-day simple moving average is $75.29. The firm has a market capitalization of $5.62 billion, a PE ratio of -24.88 and a beta of 1.20. Dianthus Therapeutics, Inc. has a 12-month low of $18.08 and a 12-month high of $107.99.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. Analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Insider Activity

In other news, SVP Adam M. Veness sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the transaction, the senior vice president owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the sale, the executive vice president owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 87,779 shares of company stock valued at $7,985,235. 3.02% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have weighed in on DNTH shares. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $117.82.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.